Neuroscience company is on the mend
This developer of digital solutions to assess brain health saw its shares tumble at the beginning of 2024 on widening losses and the unexpeceted requirement of a new high-cost loan. The latest results suggest that costs are under control and new products offer encouragement. Shareholders will need to be patient, but the valuation of this company with innovative technology looks appealing. (IHT qualifying)
According to the World Health Organisation, disorders of the brain, such as Alzheimer’s disease, Schizophrenia, Parkinson’s, depression and mental illness, are the world’s primary cause of ill health, resulting in higher costs and more hospitalisations than any other disease group. Early diagnosis of brain illnesses is desirable as it can help to reduce the costs associated with Alzheimer’s disease and dementia. Cambridge Cognition (AIM: COG) is a highly innovative AIM listed digital health technology company, committed to enhancing global research, accelerating treatment development and improving patient outcomes in conditions affecting brain health by optimising the assessment of cognition. Based on science and technology…